What is the Modified de Gramont chemotherapy regimen, including dosing, schedule, and modifications for high‑risk stage III or KRAS‑mutated metastatic disease?

Modified de Gramont Regimen

The Modified de Gramont (MdG) regimen consists of leucovorin 400 mg/m² IV over 2 hours, 5-FU 400 mg/m² IV bolus, followed by 5-FU 2400 mg/m² as a 46-48 hour continuous infusion, repeated every 2 weeks 1, 2.

Standard Dosing and Schedule

The regimen is administered fortnightly with the following components:

• Leucovorin (LV): 400 mg/m² IV infusion over 2 hours on day 1
• 5-FU bolus: 400 mg/m² IV push on day 1
• 5-FU infusion: 2400 mg/m² continuous IV infusion over 46-48 hours starting day 1
• Cycle frequency: Every 14 days

This differs from the original de Gramont regimen, which used 22-hour infusions on days 1 and 2. The modified version consolidates this into a single 46-48 hour infusion, making it more convenient for ambulatory administration 1.

Combination with Oxaliplatin (OxMdG)

When combined with oxaliplatin for stage III or metastatic disease:

• Add oxaliplatin 85 mg/m² IV over 2 hours on day 1
• Maintain the same 5-FU/LV dosing as above
• Repeat every 2 weeks

This combination (OxMdG) demonstrated a 72% objective response rate in first-line metastatic colorectal cancer 1. The regimen showed excellent tolerability with grade 3-4 neutropenia in only 2.8% of cycles and minimal gastrointestinal toxicity 1.

Clinical Context and Modifications

For High-Risk Stage III Disease

Oxaliplatin-based combinations should be used for stage III colon cancer 3. The guidelines explicitly recommend either:

• mFOLFOX6 (which uses the modified de Gramont backbone with oxaliplatin 85 mg/m² day 1, repeated every 2 weeks) 3
• FOLFOX4 (original de Gramont schedule with oxaliplatin)

Stage III patients have only 60% cure with surgery alone, making adjuvant chemotherapy with oxaliplatin combinations standard of care 3.

For KRAS-Mutated Metastatic Disease

KRAS mutation status does not alter the choice of fluoropyrimidine-based chemotherapy backbone but excludes anti-EGFR therapy 4. Recent data shows KRAS-mutant colorectal cancer has independently worse overall survival (HR 1.12 overall, HR 1.07 in stage IV disease) 4.

For KRAS-mutant metastatic disease, appropriate first-line options include:

• OxMdG + bevacizumab (oxaliplatin 85 mg/m², modified de Gramont backbone, bevacizumab 5 mg/kg every 2 weeks) 2
• FOLFIRI + bevacizumab (irinotecan-based alternative)
• FOLFOXIRI + bevacizumab for fit patients with high tumor burden requiring aggressive cytoreduction 2

Anti-EGFR antibodies (cetuximab, panitumumab) are contraindicated in KRAS-mutant disease and should never be added to these regimens 2.

Important Caveats

Toxicity Management

The most significant dose-limiting toxicity with OxMdG is cumulative oxaliplatin neurotoxicity, which led to oxaliplatin discontinuation in 27% of patients (17/62) in the pivotal study 1. Monitor for peripheral neuropathy and consider stopping oxaliplatin after 3-6 months while continuing the 5-FU/LV backbone as maintenance.

Two infection-associated deaths occurred in the original OxMdG study despite low rates of severe neutropenia, emphasizing the need for vigilant infection monitoring 1.

The Bolus Question

The clinical necessity of the 5-FU bolus before infusion remains unproven 5. No randomized trials have directly compared modified de Gramont with versus without the bolus component. Some centers omit the bolus to reduce toxicity risk, though this represents off-protocol modification 5.

Stage II Disease Considerations

For stage II colon cancer, single-agent fluoropyrimidine without oxaliplatin is generally preferred unless multiple high-risk features are present 3. The MOSAIC trial showed only a non-significant trend for improved disease-free survival with oxaliplatin addition in stage II, without overall survival benefit 3.

High-risk features warranting consideration of oxaliplatin addition include:

• T4 stage
• <12 lymph nodes examined
• Poorly differentiated histology
• Lymphovascular or perineural invasion
• Obstruction or perforation at presentation

MSI/MMR status identifies stage II patients with excellent prognosis (10-15% of cases) who derive minimal absolute benefit (1-2%) from any adjuvant chemotherapy and may reasonably forego treatment 3.